News Releases

NEEDHAM, Mass., Oct. 19, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has appointed Mace L. Rothenberg, MD, as a senior advisor to its President and Chief

NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present novel biomarker data from the ongoing phase 1 clinical trial of

NEEDHAM, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that its President and Chief Executive Officer, Paul Peter Tak, MD, PhD, FMedSci, and E.

Dr. Scott E . Eggener to present safety data from phase 2 clinical trial of CAN-2409 in patients with localized, low to intermediate risk prostate cancer undergoing active surveillance at AdMeTech Foundation’s Fifth Global Summit on Precision Diagnosis and Treatment of Prostate Cancer Dr. E.

NEEDHAM, Mass., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“the Company”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today reported financial results for the second quarter ended June 30, 2021 and provided a

NEEDHAM, Mass. , Sept. 07, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”) (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that it has completed patient enrollment for its pivotal phase 3 study of

NEEDHAM, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the closing of the issuance of an additional 887,994 shares of its common stock at a public

NEEDHAM, Mass. , July 26, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (“Candel”), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced the pricing of its initial public offering of 9,000,000 shares of common stock at a public

NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced it has appointed Diem Nguyen, Ph.D., M.B.A., to its Board of Directors. The Company also announced that Carrie S.

NEEDHAM, Mass.– Candel Therapeutics, Inc., a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced initial results from an ongoing Phase 1 clinical trial of its oncolytic virus, CAN-3110, in patients with high-grade glioma (HGG) that has